It has been reported that the CREB-binding protein (CBP) and the Bromodomain and Extra-Terminal (BET) inhibitors can reverse the abnormal activation of oncogene enhancers thus inhibiting glioma progression in the H3.3K27M-mutant gliomas [13]. This evidence concerns the gene CREBBP and glioma.